ReviewThe oncologist2012
Inflammatory breast cancer: what we know and what we need to learn.
Review in The oncologist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 147 citations in OpenAlex.
- Pervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma.Science advances · 2026Article
- Article
- Article
- Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.NPJ breast cancer · 2025Article
- How to Define Inflammatory Breast Cancer: A Systematic Review.Indian journal of surgical oncology · 2025Review
- Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.NPJ precision oncology · 2024Article
- Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.International journal of molecular sciences · 2024Article
- Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim.Radiation oncology journal · 2024Article
- New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders.Clinical breast cancer · 2024Review
- Article
- Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.International journal of molecular sciences · 2023Review
- Ten-Year Survival of Breast Cancer in Iran: A National Study (Retrospective Cohort Study).Breast care (Basel, Switzerland) · 2023Article
- Geometric tumor embolic budding characterizes inflammatory breast cancer.Breast cancer research and treatment · 2023Article
- EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.Science advances · 2022Article
- Establishment of a New Canine Inflammatory Mammary Carcinoma Cell Line and Analysis of its Cystine-glutamate Transporter Subunit Expression.Journal of veterinary research · 2022Article
- Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.Breast cancer research and treatment · 2022Review
- Characterization of Inflammatory Breast Cancer in Hispanic Women from Puerto Rico.Journal of Cancer · 2022Article
- Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines.Veterinary sciences · 2021Article
- Inflammatory breast cancer appearance at presentation is associated with overall survival.Cancer medicine · 2021Article
- Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer.Cancer research · 2021Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeWe review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease.
designWe performed a comprehensive review of the English-language literature on IBC through computerized literature searches.
resultsSignificant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (∼30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC.
conclusionOptimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.